1. Clinical & Scientific Overview
Warfarin Sodium (TIP-MED-000022, Reference Code [3.22]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Vitamin K Epoxide Reductase Complex 1 (VKORC1) Inhibitor (Oral Coumarin Anticoagulant).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.22], p. 31): Warf (Cipla), Uniwarfin (Unichem), Coumadin; Note: Acenocoumarol / Nicoumalone (Acitrom 1/2/3/4 mg - Abbott) is a closely related coumarin widely used in India with identical counselling principles — Strengths & Dosage Forms: Oral Colour-Coded Uncoated Scored Tablets: 1 mg, 2 mg, 3 mg, 5 mg
Oral Colour-Coded Uncoated Scored Tablets: 1 mg, 2 mg, 3 mg, 5 mg
3. Mechanism of Action & Pharmacodynamics
Vitamin K Epoxide Reductase Complex 1 (VKORC1) Inhibitor (Oral Coumarin Anticoagulant) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Vitamin K Epoxide Reductase Complex 1 (VKORC1) Inhibitor (Oral Coumarin Anticoagulant) for Prophylaxis and treatment of venous thromboembolism (DVT and pulmonary embolism); thromboembolism prevention in atrial fibrillation and mechanical prosthetic heart valves (where DOACs like apixaban/rivaroxaban are strictly contraindicated!) and moderate-to-severe rheumatic mitral stenosis..
4. Therapeutic Indications & Evidence-Supported Uses
- Prophylaxis and treatment of venous thromboembolism (DVT and pulmonary embolism)
- thromboembolism prevention in atrial fibrillation and mechanical prosthetic heart valves (where DOACs like apixaban/rivaroxaban are strictly contraindicated!) and moderate-to-severe rheumatic mitral stenosis
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Strictly individualised according to PT-INR! Typical maintenance ranges from 1 mg to 7 mg once daily (sometimes alternating strengths on odd/even days) to maintain target INR 2.0–3.0 (for AF, DVT/PE, aortic bileaflet mechanical valve) or INR 2.5–3.5 (for mechanical mitral valve). Never alter dose without an INR report.
Administration & Meal Timing: With or without food. | Strictly at the same evening clock hour (e.g., 06:00 PM) so that daytime morning blood draws for PT-INR allows same-day dose adjustment before the next evening dose is taken.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No routine empiric dose formula, but severe CKD (eGFR <30 mL/min) increases bleeding risk and alters protein binding — titrate strictly to target INR (2.0–3.0; or 2.5–3.5 in mechanical mitral valves) with more frequent INR checks. Hepatic: Contraindicated in severe decompensated cirrhosis with baseline coagulopathy. Reversal: Hold dose + Oral/IV Phytomenadione (Vitamin K1 1–10 mg based on INR/bleeding) + 4-Factor PCC (or FFP if PCC unavailable) for major life-threatening bleed.
Renal: No routine empiric dose formula, but severe CKD (eGFR <30 mL/min) increases bleeding risk and alters protein binding — titrate strictly to target INR (2.0–3.0; or 2.5–3.5 in mechanical mitral valves) with more frequent INR checks. Hepatic: Contraindicated in severe decompensated cirrhosis with baseline coagulopathy. Reversal: Hold dose + Oral/IV Phytomenadione (Vitamin K1 1–10 mg based on INR/bleeding) + 4-Factor PCC (or FFP if PCC unavailable) for major life-threatening bleed.
Renal: No routine empiric dose formula, but severe CKD (eGFR <30 mL/min) increases bleeding risk and alters protein binding — titrate strictly to target INR (2.0–3.0; or 2.5–3.5 in mechanical mitral valves) with more frequent INR checks. Hepatic: Contraindicated in severe decompensated cirrhosis with baseline coagulopathy. Reversal: Hold dose + Oral/IV Phytomenadione (Vitamin K1 1–10 mg based on INR/bleeding) + 4-Factor PCC (or FFP if PCC unavailable) for major life-threatening bleed.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in pregnancy (teratogenic warfarin embryopathy in 1st trimester; foetal haemorrhage near term—switch to LMWH/heparin per specialist), active major bleeding, haemorrhagic stroke, severe uncontrolled hypertension, and severe thrombocytopenia.
Key Clinical Precautions: Renal: No routine empiric dose formula, but severe CKD (eGFR <30 mL/min) increases bleeding risk and alters protein binding — titrate strictly to target INR (2.0–3.0; or 2.5–3.5 in mechanical mitral valves) with more frequent INR checks. Hepatic: Contraindicated in severe decompensated cirrhosis with baseline coagulopathy. Reversal: Hold dose + Oral/IV Phytomenadione (Vitamin K1 1–10 mg based on INR/bleeding) + 4-Factor PCC (or FFP if PCC unavailable) for major life-threatening bleed.
8. Adverse Effects Profile
- Easy bruising, prolonged bleeding from minor cuts/shaving, mild gum bleeding when brushing, epistaxis.
- Major life-threatening haemorrhage (intracranial, gastrointestinal, retroperitoneal, massive haematuria), warfarin-induced skin necrosis (within first 3–5 days in Protein C/S deficiency if started without heparin bridge), purple toe syndrome.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Extreme Interaction Potential (CYP2C9, CYP1A2, CYP3A4 & Gut Flora): • Drugs that markedly INCREASE INR & bleeding: Metronidazole, Fluconazole, Voriconazole, Cotrimoxazole (TMP-SMX), Ciprofloxacin, Levofloxacin, Azithromycin, Clarithromycin, Amiodarone, Rosuvastatin, Fenofibrate, Allopurinol, Omeprazole, Thyroxine, High-dose Paracetamol (>2 g/day for >3 days), Aspirin, Clopidogrel, NSAIDs
- • Drugs that DECREASE INR (thrombosis risk): Rifampicin, Carbamazepine, Phenytoin, Phenobarbitone, Vitamin K supplements
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Verify tablet strength by both mg number and colour (e.g., Warf 1 mg vs 2 mg vs 5 mg) at every dispensing. Instruct the patient to use a soft toothbrush and electric razor, avoid intramuscular (IM) injections, never take OTC painkillers (combiflam, diclofenac, brufen), and report immediately if INR >4.0, urine turns red/pink, stools turn black, or after any head injury/fall.
- Meal & Clock Timing Instruction: With or without food. (Strictly at the same evening clock hour (e.g., 06:00 PM) so that daytime morning blood draws for PT-INR allows same-day dose adjustment before the next evening dose is taken.)
- Missed Dose Protocol: Take on the same calendar day as soon as remembered. If not remembered until the next day, skip the missed dose, mark the date in the Anticoagulant Booklet, and inform the physician at the next INR check. Never double a warfarin dose.
- Geriatric Dispensing Pearl: Elderly patients have lower hepatic CYP2C9 clearance and heightened endothelial fragility, requiring ~30–40% lower warfarin maintenance doses. Always ask if an antibiotic or antifungal was recently started whenever dispensing to a patient on warfarin/Acitrom.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Colour-Coded Uncoated Scored Tablets: 1 mg, 2 mg, 3 mg, 5 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.22] (p. 31)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.